Which of the following conditions is NOT treated by Apixaban?

Apixaban is an anticoagulant that works by inhibiting factor Xa, which plays a crucial role in the blood coagulation sequence. It is primarily used for conditions that require the prevention or treatment of thromboembolic events.

Atrial fibrillation is treated with apixaban to reduce the risk of stroke and systemic embolism by preventing the formation of blood clots. Similarly, deep vein thrombosis (DVT) management relies on anticoagulation to prevent clots from further complicating into a pulmonary embolism (PE) or causing other issues. Pulmonary embolism is also effectively treated with apixaban to dissolve or prevent clots from forming in the pulmonary arteries, which can be life-threatening.

In contrast, coronary artery disease (CAD) is typically managed with different classes of medications like antiplatelet agents (e.g., aspirin or clopidogrel), statins, beta-blockers, and other cardiovascular agents aimed at improving blood flow and heart function, rather than directly affecting clot formation in the manner that apixaban does. Therefore, CAD does not fall under the conditions treated by apixaban. This distinction clarifies why this condition is associated with the correct answer in the question.